Boehringer Obesity Shot Prompts 16.6% Weight Loss in Trial

Boehringer Ingelheim GmbH said patients using its experimental obesity shot lost 16.6% of their body weight in a large study, disappointing hopes it could outperform Eli Lilly & Co.’s market leader Zepbound.

Patients in the trial shed the weight after 76 weeks of treatment with survodutide, compared with 3.2% weight loss for those given a placebo, Boehringer said Tuesday. Key details are still to be reported on side effects, patient dropouts, liver benefit and how much of the weight loss was from fat, which will help determine how competitive the drug can be.